US Stock MarketDetailed Quotes

ACRV Acrivon Therapeutics

Watchlist

5.690
-0.330-5.48%

Close Jan 2 16:00 ET

5.690
0.0000.00%

Post 20:01 ET

177.17MMarket Cap-2.14P/E (TTM)

Acrivon Therapeutics Stock Forum

Trytosaveabit

Apr 25, 2024 08:07

Again! Wish I had confidence in Analysts! Hehehe

$Acrivon Therapeutics (ACRV.US)$ Acrivon Therapeutics Price Target Raised to $30.00/Share From $26.00 by Piper Sandler
Dow Jones· 2 mins ago

Trytosaveabit

Apr 24, 2024 15:23

Hmm?

$Cidara Therapeutics (CDTX.US)$ $Acrivon Therapeutics (ACRV.US)$ Same people trading both? Hehehe charts look very similar. At least as i post this! Hehehe

Trytosaveabit

Apr 24, 2024 15:13

Note the date

$Acrivon Therapeutics (ACRV.US)$ Acrivon Therapeutics: Acr-2316, a Potential First-in-Class Dual Wee1/Pkmyt1 Inhibitor, Ind Timeline Accelerated With Filing Now Expected in Q3 2024

Trytosaveabit

Apr 24, 2024 15:10

Nice

$Acrivon Therapeutics (ACRV.US)$ Acrivon Therapeutics: A 50% Confirmed Overall Response Rate Showed With Acr-368 in Oncosignature-Positive Gynecological (Ovarian, Endometrial) Cancers

Jaguar8

Apr 16, 2024 22:22

$Acrivon Therapeutics (ACRV.US)$
NEWS
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matche...

JESSE JAMES8832

Apr 15, 2024 15:29

and another huge buy 3.5m

$Acrivon Therapeutics (ACRV.US)$

JESSE JAMES8832

Apr 15, 2024 09:36

wow big insider loading 2.5m

$Acrivon Therapeutics (ACRV.US)$

Jaguar8

Apr 10, 2024 07:06

$Acrivon Therapeutics (ACRV.US)$
NEWS
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclin...

Stock Region

Apr 9, 2024 14:53

$130 Million Private Placement Financing Secured By Therapeutics Company For Cancer Treatment

Acrivon Therapeutics Secures $130 Million in Private Placement Financing: A Leap Forward in Cancer Treatment Innovation.
In an era where the battle against cancer continues to demand innovative solutions, Acrivon Therapeutics has taken a significant step forward by securing $130 million through private placement financing. This move not only underscores the biotech industry's confidence in Acrivon's pote...